Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc to Discuss Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress Transcript

Jun 07, 2020 / 12:30PM GMT
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals conference call to discuss results from the ILLUMINATE-A Phase III study. There will be a question-and-answer session to follow. Please be advised that this call is being taped at the company's request.

I would now like to turn the call over to the company.

Christine Regan Lindenboom
Alnylam Pharmaceuticals, Inc. - Senior VP of IR & Corporate Communications

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, our Chief Executive Officer; Akshay Vaishnaw, our President of R&D; and Barry Greene, our President. Also joining us and available for Q&A are Yvonne Greenstreet, our Chief Operating Officer; Pushkal Garg, our Chief Medical Officer; and Pritesh Gandhi, General Manager of the Lumasiran Program. For those of you participating via conference call, the slides will be made available via webcast and also be accessed by going to the Investors page of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot